Report Adverse Event or Product Quality Complaint   US Site   Global Site             

Header Logo
  • Prescribing Information
  • Therapy areas
    • All Therapeutic Areas
    • Cardiovascular, Renal and Metabolism
    • Immunology
    • Infection
    • Oncology
    • Rare Disease (Alexion)
    • Respiratory
  • Disease Education
  • Resources
    • Congress Library
    • Clinical Trials
    • Continuing Education
    • Patient Support
    • Pipeline
  • Connect
    • Connect with an MSL
    • Connect with an MSL
    • Submit an MIR
    • Give Feedback

Search Medical Information

Login

Request a field medical follow-up

  • Home
  • Congress Library
  • American College of Allergy, Asthma & Immunology - 2025 Annual Scientific Meeting

American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting 2025

November 6 - 10, 2025

  1. All
  2. FASENRA (benralizumab)
  3. TEZSPIRE (tezepelumab)
  4. AIRSUPRA (albuterol/budesonide)
  5. Respiratory Unbranded

PDF

Model-based comparison of eosinophilic depletion following treatment with benralizumab, depemokimab and mepolizumab

PDF

CROSSROADS-3: Real-world reduction of exacerbations, healthcare utilization and corticosteroid use with tezepelumab in severe asthma

PDF

Reduction in exacerbations increased over time in US real-world severe asthma patients initiating tezepelumab: CROSSROADS-4

PDF

Tezepelumab efficacy in patients with severe, uncontrolled asthma by exacerbation triggers in NAVIGATOR and DIRECTION

PDF

Efficacy of biologics in patients with severe, uncontrolled chronic rhinosinusitis with nasal polyps

PDF

Clinical outcomes after tezepelumab cessation following 52 weeks of treatment in adults with severe CRSwNP

PDF

Sense of smell improvements with tezepelumab in patients with chronic rhinosinusitis with nasal aolyps (WAYPOINT)

PDF

Tezepelumab treatment improves rhinosinusitis symptoms and HRQoL across SNOT-22 domains in adults with severe CRSwNP

HTML

Tezepelumab in Allergic Rhinitis and asthma Study (TEZARS): Improvement in nasal symptoms 6-months post-treatment

PDF

Real-World impact of tezepelumab on exacerbations, healthcare utilization, and costs among US patients (CROSSROADS-1)

PDF

Combination short-acting bronchodilator and inhaled corticosteroid rescue therapy (the ANCHOR Study): rationale and design

PDF

Albuterol-budesonide treatment in acute airway obstruction: onset and duration of lung function and symptom improvement

PDF

Use of as-needed albuterol-budesonide versus albuterol before and after a severe exacerbation: BATURA post-hoc analysis

PDF

Patient characteristics from MT RAINIER: asthma quality improvement program across multi-site allergy community practices

PDF

Model-based comparison of eosinophilic depletion following treatment with benralizumab, depemokimab and mepolizumab

PDF

CROSSROADS-3: Real-world reduction of exacerbations, healthcare utilization and corticosteroid use with tezepelumab in severe asthma

PDF

Reduction in exacerbations increased over time in US real-world severe asthma patients initiating tezepelumab: CROSSROADS-4

PDF

Tezepelumab efficacy in patients with severe, uncontrolled asthma by exacerbation triggers in NAVIGATOR and DIRECTION

PDF

Efficacy of biologics in patients with severe, uncontrolled chronic rhinosinusitis with nasal polyps

PDF

Clinical outcomes after tezepelumab cessation following 52 weeks of treatment in adults with severe CRSwNP

PDF

Sense of smell improvements with tezepelumab in patients with chronic rhinosinusitis with nasal aolyps (WAYPOINT)

PDF

Tezepelumab treatment improves rhinosinusitis symptoms and HRQoL across SNOT-22 domains in adults with severe CRSwNP

HTML

Tezepelumab in Allergic Rhinitis and asthma Study (TEZARS): Improvement in nasal symptoms 6-months post-treatment

PDF

Real-World impact of tezepelumab on exacerbations, healthcare utilization, and costs among US patients (CROSSROADS-1)

PDF

Combination short-acting bronchodilator and inhaled corticosteroid rescue therapy (the ANCHOR Study): rationale and design

PDF

Albuterol-budesonide treatment in acute airway obstruction: onset and duration of lung function and symptom improvement

PDF

Use of as-needed albuterol-budesonide versus albuterol before and after a severe exacerbation: BATURA post-hoc analysis

PDF

Patient characteristics from MT RAINIER: asthma quality improvement program across multi-site allergy community practices

Disclaimer

Some content may have changed since publication. Some links may require registration/login to access the content. Any attached publications and/or any tables or figures derived from the publications are copyright-protected works. AstraZeneca has obtained permission from the copyright owner to use this work on this site. You may not reproduce, prepare derivative works from, display or distribute this work unless you obtain the permission of the copyright owner, or as otherwise might be permitted by law.

Connessiallasalute.it

This site is intended for healthcare professionals practicing in the US.
©2026 AstraZeneca. All rights reserved.

US-107328
Last Updated 3/26

Contact Us

About Us

AstraZeneca-US.com

Grant Opportunities  

Survey Feedback

Your Privacy Choice

Consumer Health Data 
Privacy Notice

Privacy Notice | Legal Notice | Cookie Preferences

Welcome to AstraZeneca Medical Information

The information provided on this site is intended for use by healthcare professionals practicing in the US. The dissemination of this information may be subject to different medical and regulatory requirements in other countries.

 

This web site is intended to help healthcare professionals practicing in the US and AstraZeneca authorized persons find scientifically balanced, evidence-based information about AstraZeneca drugs, submit a question, ask for field medical follow-up, and explore links to professional and patient support resources.

 

Are you a healthcare professional practicing in the United States?

I am an AstraZeneca authorized person   What is an AstraZeneca authorized person?
This website is only intended for healthcare professionals practicing in the United States and authorized AstraZeneca personnel. AstraZeneca US Headquarters personnel and US Field Medical personnel are authorized to browse and search the database for their own background knowledge and insight. US Field Sales personnel should not access or browse this site. None of the content of this site should be directly linked or distributed without approval.
I am not a healthcare professional practicing in the United States